WallStreetZen

NASDAQ: NMTR
9 Meters Biopharma Inc Stock

$1.080.00 (0.00%)
Updated Jul 30, 2021
NMTR Price
$1.08
Fair Value Price
N/A
Market Cap
$271.48M
52 Week Low
$0.45
52 Week High
$2.26
P/E
-1.83x
P/B
7.97x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$63.32M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.18
Operating Cash Flow
-$23M
Beta
0.67
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

NMTR Overview

Zen Score

High
Medium
Low
13
Industry average

Reasons for this score

NMTR is poor value based on its book value relative to its share price (7.97x), compared to the US Biotechnology industry average (6.85x)
Valuation
NMTR's cash and short-term investments ($38.57M) cannot cover NMTR's cash burn for the next year ($23.01M), once increasing cash burn (101.23%) is accounted for
Financials
NMTR's short-term assets ($39.98M) exceed its short-term liabilities ($5.99M)
Financials

1 of 5

NMTR News

Valuation

NMTR fair value

Fair Value of NMTR stock based on Discounted Cash Flow (DCF)
Price
$1.08
Fair Value
$1.28
Undervalued by
15.77%

NMTR price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.83x
Industry
279.56x
Market
31.55x

NMTR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
7.97x
Industry
6.85x
NMTR is poor value based on its book value relative to its share price (7.97x), compared to the US Biotechnology industry average (6.85x)
Valuation

NMTR's financial health

Profit margin

Revenue
$0.0
Net Income
-$5.4M
Profit Margin
0%
NMTR's cash and short-term investments ($38.57M) cannot cover NMTR's cash burn for the next year ($23.01M), once increasing cash burn (101.23%) is accounted for
Financials

Assets to liabilities

Assets
$40.2M
Liabilities
$6.1M
Debt to equity
0
NMTR's short-term assets ($39.98M) exceed its short-term liabilities ($5.99M)
Financials
NMTR's short-term assets ($39.98M) exceed its long-term liabilities ($154.85k)
Financials
NMTR's debt to equity ratio (0.18) is considered acceptable
Financials

Cash flow

Operating
-$6.2M
Investing
-$5.0k
Financing
$6.9M
NMTR's cash and short-term investments ($38.57M) can cover NMTR's cash burn ($23.01M) for at least 1 year
Financials

9 Meters Biopharma Stock FAQ

What is 9 Meters Biopharma's quote symbol?

(NASDAQ: NMTR) 9 Meters Biopharma trades on the NASDAQ under the ticker symbol NMTR. 9 Meters Biopharma stock quotes can also be displayed as NASDAQ: NMTR.

What is the 52 week high and low for 9 Meters Biopharma (NASDAQ: NMTR)?

(NASDAQ: NMTR) 9 Meters Biopharma's 52-week high was $2.26, and its 52-week low was $0.45. It is currently -52.21% from its 52-week high and 139.47% from its 52-week low.

How much is 9 Meters Biopharma stock worth today?

(NASDAQ: NMTR) 9 Meters Biopharma currently has 251,372,296 outstanding shares. With 9 Meters Biopharma stock trading at $1.08 per share, the total value of 9 Meters Biopharma stock (market capitalization) is $271.48M.

9 Meters Biopharma stock was originally listed at a price of $36.80 in Jul 8, 2016. If you had invested in 9 Meters Biopharma stock at $36.80, your return over the last 5 years would have been -97.07%, for an annualized return of -50.62%.

How much is 9 Meters Biopharma's stock price per share?

(NASDAQ: NMTR) 9 Meters Biopharma stock price per share is $1.08 today (as of Jul 30, 2021).

What is 9 Meters Biopharma's Market Cap?

(NASDAQ: NMTR) 9 Meters Biopharma's market cap is $271.48M, as of Aug 1, 2021.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

9 Meters Biopharma's market cap is calculated by multiplying NMTR's current stock price of $1.08 by NMTR's total outstanding shares of 251,372,296.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.